---
title: "NewcelX reports successful FDA pre-IND meeting for NCEL-101 type 1 diabetes trial plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291578605.md"
description: "NewcelX reported a successful FDA Type B pre-IND meeting for its NCEL-101 type 1 diabetes trial plan. The FDA supported the company's CMC package and preclinical program, enabling progress into IND-enabling work. The development plan pairs NCEL-101 with Eledon’s tegoprubart as a calcineurin inhibitor-free immunosuppression approach."
datetime: "2026-07-02T18:32:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291578605.md)
  - [en](https://longbridge.com/en/news/291578605.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291578605.md)
generator: "portal-rs"
---

# NewcelX reports successful FDA pre-IND meeting for NCEL-101 type 1 diabetes trial plan

-   NewcelX reported a successful FDA Type B pre-IND meeting for NCEL-101 in type 1 diabetes, outlining a clear path toward starting clinical trials. \* FDA feedback supported the company’s CMC package and preclinical program, enabling progress into IND-enabling work. \* Development plan pairs NCEL-101 with Eledon’s tegoprubart as a calcineurin inhibitor-free immunosuppression approach. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NCEL.US](https://longbridge.com/en/quote/NCEL.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [NLSP.US](https://longbridge.com/en/quote/NLSP.US.md)
- [NLSPW.US](https://longbridge.com/en/quote/NLSPW.US.md)

## Related News & Research

- [Eledon to Present Long-Term Tegoprubart Data at Transplantation Society Congress](https://longbridge.com/en/news/298445719.md)
- [Eledon submits FDA IND for tegoprubart islet cell transplant trial in type 1 diabetes](https://longbridge.com/en/news/297902220.md)
- [OCUL: AXPAXLI advances toward 2027 launch with robust clinical data, FDA alignment, and strong commercial plans](https://longbridge.com/en/news/299076641.md)
- [BriaCell DSMB flags no safety issues, backs continued Phase 3 metastatic breast cancer trial of Bria-IMT plus checkpoint inhibitor](https://longbridge.com/en/news/298911002.md)
- [PALI: Phase II trials for a novel oral PDE4 inhibitor in UC and Crohn's are fully funded and underway](https://longbridge.com/en/news/299202156.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**